Article

Mild cognitive impairment

McGill Center for Studies in Aging, Douglas Hospital, Montréal, Quebec, Canada.
The Lancet (Impact Factor: 45.22). 05/2006; 367(9518):1262-70. DOI: 10.1016/S0140-6736(06)68542-5
Source: PubMed

ABSTRACT

Mild cognitive impairment is a syndrome defined as cognitive decline greater than expected for an individual's age and education level but that does not interfere notably with activities of daily life. Prevalence in population-based epidemiological studies ranges from 3% to 19% in adults older than 65 years. Some people with mild cognitive impairment seem to remain stable or return to normal over time, but more than half progress to dementia within 5 years. Mild cognitive impairment can thus be regarded as a risk state for dementia, and its identification could lead to secondary prevention by controlling risk factors such as systolic hypertension. The amnestic subtype of mild cognitive impairment has a high risk of progression to Alzheimer's disease, and it could constitute a prodromal stage of this disorder. Other definitions and subtypes of mild cognitive impairment need to be studied as potential prodromes of Alzheimer's disease and other types of dementia.

Download full-text

Full-text

Available from: Harald J Hampel, Jul 25, 2014
  • Source
    • "Depression was listed as one of the most frequent, with a majority of authors reporting prevalences of 20–50%, depending on sampling and diagnostic criteria (Apostolova and Cummings, 2008). Although MCI affects memory to a certain extent, it does not represent a major impact on daily life activities (Gauthier et al., 2006). However, while some patients remain stable or even recover normal cognition, 20–40% of MCI patients progress to AD or other dementias within a few years, a much higher proportion than in cognitively normal elderly individuals (Roberts and Knopman, 2013). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) and major depressive disorder (MDD) are highly prevalent neuropsychiatric conditions with intriguing epidemiological overlaps. Depressed patients are at increased risk of developing late-onset AD, and around one in four AD patients are co-diagnosed with MDD. Microglia are the main cellular effectors of innate immunity in the brain, and their activation is central to neuroinflammation - a ubiquitous process in brain pathology, thought to be a causal factor of both AD and MDD. Microglia serve several physiological functions, including roles in synaptic plasticity and neurogenesis, which may be disrupted in neuroinflammation. Following early work on the 'sickness behavior' of humans and other animals, microglia-derived inflammatory cytokines have been shown to produce depressive-like symptoms when administered exogenously or released in response to infection. MDD patients consistently show increased circulating levels of pro-inflammatory cytokines, and anti-inflammatory drugs show promise for treating depression. Activated microglia are abundant in the AD brain, and concentrate around senile plaques, hallmark lesions composed of aggregated amyloid-β peptide (Aβ). The Aβ burden in affected brains is regulated largely by microglial clearance, and the complex activation state of microglia may be crucial for AD progression. Intriguingly, recent reports have linked soluble Aβ oligomers, toxins that accumulate in AD brains and are thought to cause memory impairment, to increased brain cytokine production and depressive-like behavior in mice. Here, we review recent findings supporting the inflammatory hypotheses of AD and MDD, focusing on microglia as a common player and therapeutic target linking these devastating disorders.
    Full-text · Article · Nov 2015 · Brain Behavior and Immunity
  • Source
    • "Tel.: +34 92621532; Fax: +34 927256202; E-mail: icasadon@gmail.com. education level, but which creates little to no interference with activities of daily life [1]. According to this definition, MCI has neither a specific outcome nor a specific etiology [2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and objective: Current evidence shows that numerous classic vascular risk factors (VRF) contribute to mild cognitive impairment (MCI), but the effects of emerging VRFs are less well-known. Using a comprehensive approach, we assessed the frequency and strength of association between MCI and classic VRFs, subclinical markers of atherosclerosis (cystatin C, lipoprotein(a), high-sensitivity C-reactive protein, and intima-media thickness) and white matter hyperintensities (WMH). Methods: In this case-control study of consecutive MCI patients and cognitively normal controls, subjects underwent clinical and neuropsychological examinations, laboratory analyses, a carotid duplex scan, and a brain magnetic resonance imaging scan. Results: The study included 105 patients with amnestic MCI (aMCI): 24 with single domain amnestic MCI, 81 with multiple domain amnestic MCI, and 76 controls. Compared to controls, patients with aMCI were significantly older and had higher rates of arterial hypertension, atrial fibrillation, and depression. They also had a larger intima-media thickness and higher load of WMHs, both periventricular (WMHpv) and subcortical (WMHsc). In the adjusted analysis, all variables except WMHsc displayed a significant association with aMCI. Body mass index exerted a protective effect. Conclusions: Our findings suggest a direct association between aMCI and age, hypertension, atrial fibrillation depression, intima-media thickness, and WMHpv. Body mass index has a protective effect on this MCI subtype.
    Full-text · Article · Oct 2014 · Journal of Alzheimer's disease: JAD
  • Source
    • "The objective of this review is to explore the utility of using transcranial ultrasound to diagnose AD, especially its preclinical or mild clinical stages of mild cognitive impairment (MCI). However, it is not clear whether MCI, and specifically its amnestic subtype, represents a translational stage of evolving dementia or is just an additional risk factor for AD [10]. We also discuss whether there is a special transcranial Doppler sonography (TCD) pattern of circulation impairment in AD and MCI compared with VaD and healthy control subjects. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a progressive, neurodegenerative disease characterized by an increasing incidence. One of the pathologic processes that underlie this disorder is impairment of brain microvasculature. Transcranial ultrasound is a non-invasive examination of cerebral blood flow that can be employed as a simple and useful screening tool for assessing the vascular status of brain circulation in preclinical and clinical stages of AD. The objective of this review is to explore the utility of using a transcranial ultrasound to diagnose AD. With transcranial ultrasound, the most frequently studied parameters are cerebral blood flow velocities and pulsatility indices, cerebrovascular reserve capacity, and cerebral microembolization. On the basis of current knowledge, we recommend using as a transcranial Doppler sonography screening method of choice the assessment of cerebrovascular reserve capacity with breath-holding test.
    Full-text · Article · Oct 2014 · Journal of Alzheimer's disease: JAD
Show more